Procavea Biotech AG
First-in-class adrenal siRNA delivery system
Procavea Biotech AG is an ETH Zurich spin-off advancing a first-in-class siRNA delivery platform. While standard systems are restricted to liver delivery, Procavea’s proprietary OP protein cage enables extrahepatic delivery, specifically targeting the adrenal cortex - a region previously unreachable by RNAi. The lead program, PCV-001, targets Primary Aldosteronism, converting a validated pathway into a durable, quarterly-dosed therapy. Procavea employs a hybrid business model: developing an internal adrenal pipeline while partnering with pharma to enable delivery to tissues like the CNS and kidney.
Only registered users have access to funding information.
Please log in or register to continue. Registration is free.
31.10.2025
More than 20 Swiss biotech companies to exhibit at Bio Europe (startupticker.ch)
15.05.2024
TOP 18 startups contest further for the >>venture>> Award (startupticker.ch)
No Jobs
No videos and documents
Venture Kick
Venture Kick supports potential entrepreneurs with start capital up to CHF 150'000 as well as hands-on execution support and access to a nationwide network of investors and experts in the startup field. Multiple times per year, 8 selected projects get the opportunity to present their business ideas in front of a panel. The 5 most promising projects enter the support process. After 9 months at the latest, the startups incorporate and enter the market. Since 2007, Venture Kick has invested over CHF 58 million in over 1111 projects.
Procavea Biotech AG
First-in-class adrenal siRNA delivery system
Website:
www.procavea.com
Headquarter:
Zürich ETH-Hönggerberg
Foundation Date:
February 2024
Technology:
- Biotech
Sectors:
- Biotech
- Cardiovascular
- Drug development platforms
- Drug discovery
Support received
